GLP1R and type 2 diabetes mellitus: This systematic review evaluates the cardiovascular and renal outcomes associated with sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists in patients with type 2 diabetes, focusing on findings from randomized controlled trials.